Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer (NCT06125197)
A Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Immune Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
Who can join: Review the eligibility criteria below.
Location: Hoag Memorial Hospital Presbyterian — Newport Beach, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- UCLA Jonsson Comprehensive Cancer Center — Santa Monica, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer
- Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
- Early Detection of Lung Cancer — Nashville, Tennessee
- Improving Utilization of Lung Cancer Screening in Underserved PA Populations — Allentown, Pennsylvania
- Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting — Houston, Texas
- Testing the Engaged Approach to Lung Cancer Screening — Denver, Colorado
- Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer — Boston, Massachusetts
Explore by condition: All Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.